Cartilage derived peptacans: Novel nutraceuticals with immunomodulatory, anti-inflammatory and anti-arthritic activities

Current Topics in Nutraceutical Research

Volumn 6, Issue 2, 2008, Pages 83-98

  Ghosh, Peter ^a   Shimmon, Susan ^a   Wilson Ghosh, Nancy ^a   Whitehouse, Michael ^b,c  

^a Institute of Nutraceutical Research   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Arthritis; Inflammation; Oral tolerization; Peptacans

Indexed keywords

CALCIUM PEPTACAN; CHONDROITIN SULFATE; COLLAGEN TYPE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOSAMINE; GLUCOSAMINE SULFATE; GLYCOSAMINOGLYCAN PEPTIDE; MAGNESIUM PEPTACAN; PEPTACAN; UNCLASSIFIED DRUG; ZINC PEPTACAN;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; CARTILAGE DEGENERATION; CHEMICAL STRUCTURE; DOSE RESPONSE; DRUG FORMULATION; DRUG ISOLATION; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LOW DRUG DOSE; NONHUMAN; OSTEOARTHRITIS; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALIA; BOVINAE; ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 54949091475     PISSN: 15407535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Aithal GP, Day CP. (2007) Nonsteroidal antiinflammatory drug-induced hepatotoxicity. Clinics in Liver Diseases 11:563-75.
2. Adebowale AO, Cox DS, Liang Z, Eddington ND. (2000) Analysis of glucosamine and chondroitin sulfate content in marketed products and caco-2 permeability of chondroitin sulfate raw materials. Journal American Nutritional Association 3:37-44.
3. Alsalameh S, Mollenhauer J, Hain N, Stock K-P, Kalden JR, Burmester GR. (1990) Cellular immune response toward human articular chondrocytes. Arthritis Rheumatism 33:1477-1486.
4. Banerjee S, Poole AR. (1992) Immunity to cartilage proteoglycans. Journal Rheumatology 19:36-39.
5. Barnett ML, Combitchi D, Trentham DE. (1996) A pilot study of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheumatism 39:623-628.
6. Birkedal-Hansen H, Moore WG, Bodden MK, Winsor LJ, Birkdal-Hansen B, Mann W, Furie M. (1993) Matrix metalloproteinases: a review. Critical Reviews Oral Biology Medicine 197:197-250.
7. Brandt KD. (1993) Should nonsteroidal antiinflammatory drugs be used to treat osteoarthritis? Rheumatic Disease Clinics of North America 19:29-44.
8. Bruyere O, Reginster JY. (2007) Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs and Aging 24:573-80.
9. Burton B. (2007) Australian drugs regulator cancels registration of COX II inhibitor. British Medical Journal 335:363.
10. Cambray GJ, Murphy G, Reynolds JJ. (1981) The effects of dexamethasone in vitro on the production of collagenase and inhibitor by synovial and cartilage explants from joints of rabbits with a proliferative arthritis. Rheumatobgy International 1:69-72.
11. Campbell JD. (2001) Lifestyle, minerals and health. Medical Hypothesis 57:521-531.
12. Carlsen S, Hansson AS, Olsson H, Heinegard D, Holmdahl R. (1998) Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats. Clinical Experimental Immunology 114:477-84.
13. Choy EH, Scott DL, Kingsley GH, Thomas S, Murphy AG, Staines N, Panayi GS. (2001) Control of arthritis by oral tolerance. Arthritis Rheumatism 44:1993-7.
14. Clegg DO, Reda DJ, Harris CL, Klein MA. (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal Medicine 354:795-808.
15. Cremer MA, Rosloniec EF, Kang AH. (1998) The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. Journal Molecular Medicine 76:275-288.
16. Dahl IMS, Husby G. (1985) Hyaluronic acid production in vitro by synovial lining cells from normal and rheumatoid joints. Annals Rheumatic Diseases 44:647-657.
17. Deal CL, Moskowitz RW. (1999) Nutraceuticals as therapeutic agents in osteoarthritis. Rheumatic Disease Clinics of North America 25:379-395.
18. Eyre DR, Wu J-J, Woods P. (1992) Cartilage-specific collagens: structutal studies. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC (Eds), Articular Cartilage and Osteoarthritis (New York: Raven Press), pp.119-132.
19. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA. (2000) Osteoarthritis: New insights. Annals Internal Medicine 133:635-646.
20. Fox C, Ramsoomair D, Carter CF. (2001) Magnesium: its proven and potential clinical significance. Southern Medical Journal 94:1195-1201.
21. Fuchs SM, Schliemann-Willers S, Fischer TW, Elsner P. (2005) Protective effects of different marigold (Calendula officinalis L.) and rosemary cream preparations against sodium-lauryl-sulfate induced irritant contact dermatitis. Skin Pharmacology Physiology 18:195-200.
22. Ghosh P, Guidolin D. (2002) Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Seminars Arthritis Rheumatism 32:10-37.
23. Ghosh P, Shimmon S, Whitehouse M. (2006) Arthritic disease suppression and cartilage protection with glycosaminoglycan polypeptide complexes (Peptacans) derived from the cartilage extracellular matrix: a novel approach to therapy. Inflammopharmacology 54:161-168.
24. Ghosh P, Shimmon S, Whitehouse MW. (2005) The immunological basis for inflammation and cartilage destruction in osteoarthritis. New opportunities for therapeutic intervention. Reumatismo 57:110-112.
25. Ghosh P, Smith MM, Burkhardt D, Kipic B, Swain M, Cake M, Read R. (2005) Preclinical studies on the pharmacology of hyaluronan in relation to its application as an intra-articular therapy for the treatment of osteoarthritis. In: Balazs EA, Hascall VC. (Eds), Hyaluronan, structure, metabolism, biological activities, therapeutic applications Volume II. (New Jersey: Matrix Biology Institute), pp. 491-502.
26. Ghosh P. (2007). Topical compositions for the treatment, protection and restoration of skin and connective tissues. US patent No 7,211,648 B2.
27. Glant TT, Buzas EI, Finnegan A, Negroiu G, Cs-Szabo G, Mikecz K. (1998) Critical roles of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen recognition and presentation. Journal Immunology 160:3812-381.
28. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 365:475-81.
29. Gums JG. (2004) Magnesium in cardiovascular and other disorders. American Journal Health-System Pharmacology 61:1569-576.
30. Hardingham TE, Fosang AJ, Dudhia J (1992) Aggrecan, the chondroitin sulfate/keratan sulfate proteoglycan from cartilage. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC (Eds), Articular Cartilage and Osteoarthritis (New York: Raven Press), pp. 5-20.
31. Hedbom E, Hauselmann HJ. (2002) Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Molecular Life Science 59:45-53.
32. Heinegård DK, Pimentel ER. (1992) Cartilage Matrix proteins. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC (Eds), Articular Cartilage and Osteoarthritis (New York: Raven Press), pp. 95-112.
33. Hochberg M. (2006) Nutritional supplements for knee osteoarthritis - still no resolution. New England Journal Medicine 354:858-860.
34. Holmdahl R, Malmstrom V, Vuorio E. (1993) Autoimmune recognition of cartilage collagens. Annuals Medicine 25:251-264.
35. Hua J, Sugura S, Hirano S, Sakamoto K, Nagaoka I. (2005) Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflammation Research 54:127-32.
36. Huskisson EC, Berry H, Gishen P, Jubb RW, Whitehead J. (1995) Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. Journal of Rheumatology 22:1941-6.
37. Ilic MZC, Handley CJ, Robinson HC, Mok MT. (1992) Mechanism of catabolism of aggrecan by articular cartilage. Archives Biochemistry Biophysics 294:115-122.
38. Kagsnoff MF. (1996) Oral Tolerance: mechanisms and possible role in inflammatory joint diseases. Bailliere's Clinical Rheumatology 1996; 10:41-54.
39. Kobayashi K, Mishima H, Hashimoto S, Goomer RS, Harwood FL, Lotz M. (2001) Chondrocyte apoptosis and regional differential expression of nitric oxide in the medial meniscus following partial meniscectomy. Journal Orthopaedic Research 19:802-808.
40. Konttinen YT, Li T-F, Hukkanen M, Ja J, Xu J-W, Virtanen I. (2000) Fibroblast biology: signals targeting the synovial fibroblast in arthritis. Arthritis Research 2:348-355.
41. Lech T. (2001) Calcium and magnesium content in hair as a predictor of disease in children. Part II: disorders of the osteomusculararticular system. Trace Elements and Electrolytes 18:165-171.
42. Lichtenstein DR, Syngal S, Wolfe MM. (1995) Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheumatism 28:5-18.
43. Lohmander S, Saxne T, Heinegard D. (1995) Molecular markers for joint and skeletal diseases. Acta Orthopaedica Scandia 66:Supplement 266.
44. Mayes RW, Mason RM, Griffin DC. (1973) The composition of cartilage proteoglycans. An investigation using high- and low-ionic-strength extraction procedures. Biochemical Journal 131:541-53.
45. McAlindon TE, Lo GH. (2007) Nutritional and nutritional supplement interventions for OA. In: Sharma L., Berenbaum F. (Eds), Osteoarthritis (Philadelphia: Mosby Elsevier), pp. 257-261.
46. McKown KM, Carbone LD, Kaplan SB, Aelion JA et al. (1999) Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid atthritis. Arthritis Rheumatism 42:1204-1208.
47. Moe SM. (2005) Disorders of calcium, phosphorus and magnesium. American Journal Kidney Diseases 45:213-18.
48. Moore RA, Derry S, McQuay HJ. (2007) Cyclo-oxygenase-2 selective inhibitors and nonsteroidal antiinflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskeletal Disorders 8:73.
49. Myers LK, Rosloniec EF, Creamer MA, Kang AH. (1997) Collagen-induced arthritis, an animal model of autoimmunity. Science 19:1861-1878.
50. Oikarinen A, Haapasaari KM, Sutinen M, Tasanen K. (1998) The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. British Journal Dermatology 139:1106-10.
51. Omata T, Itokazu Y, Inoue N, Segawa Y. (2000) Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Drug Research 50:148-153.
52. Page-Thomas DP. (1977) Aspects of synovial degradation. Bayer-Symposium, Experimental models of chronic inflammatory disease. (Berlin: Springer-Verlag); 353-365.
53. Pelletier J-P, Martel-Pelletier J, Abramson SB. (2001) Osteoarthritis, an inflammatory disease. Potential implications for the selection of new therapeutic targets. Arthritis Rheumatism 44:1237-1247.
54. Poole CA. (1992) The chondrocyte and its pericellular microenvironment. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC (Eds), Articular Cartilage and Osteoarthritis (New York: Raven Press), pp. 201-220.
55. Prakken BJ, Roord S, van Kootgen PJ, Wagenaar JP, van Eden W, Albani S, Wauben MH. (2002) Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analogue of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheumatism 46:1937-946.
56. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O. (2001) Long term effect of glucosamine sulfate on osteoarthritis progression: a randomised placebo-controlled clinical trial. Lancet 27:251-65.
57. Saito N. (2004) Bone mineral density, serum albumin and serum magnesium. Journal American College Nutrition 23:701S-3S.
58. Sakkas LI, Platsoucas CD. (2007) The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheumatism 56:2409-424.
59. Sandy JD. (2006) A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 14:95-100.
60. Schoepe S, Schäcke H, May E, Asadullah K. (2006) Glucocorticoid therapy-induced skin atrophy. Experimental Dermatology 15:406-20.
61. Schulze-Koops H, Kalden JR. (2001) The balance of Th1-Th2 in rheumatoid arthritis. In: Breedveld F, Brooks P. (Eds), Pharmacopathogenesis (Bailliere's Clin Rheumatology) pp., 677-691.
62. Seelig M. (2006) Cardiovascular consequences of magnesium deficiency and loss: pathogenesis, prevalence and manifestations - magnesium and chloride loss in refractory potassium repletion. American Journal Cardiology 98:140.
63. Shen B, Ghosh P. (2005) Nutraceuticals for treatment, protection and restoration of connective tissues. Australian Patent 2003201402 2005.
64. Sieper J, Kary S, Sorenson H, Alten R, Eggens U, Huge W. (1996) Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheumatism 39:41-511.
65. Smith M, Ghosh P, Numata Y, Bansal MK. (1994) The effects of orally administered calcium pentosan polysulfate on inflammation and cartilage degradation produced in rabbit joints by intraarticular injection of a hyaluronate-polylysine complex. Arthritis and Rheumatism 37:125-136.
66. 't Hart BA, Bakker NPM, Jonker M, Bontrop RE. (1993) Resistance to collagen-induced arthritis in rats and rhesus monkeys after immunization with attenuated type II collagen. European Journal Immunology 23:251-264.
67. Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. (1994) Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochemical Biophysical Research Communications 200:142-8.
68. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL. (1993) Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727-1730.
69. Wang JY, Roehrl MH. (2002) Glycosaminoglycans are a potential cause of rheumatoid arthritis. Proceedings National Academy Science (USA) 99:14362-14367.
70. Weiner HL. (1994) Oral tolerance. Proceedings National Academy Science (USA) 23:10762-10765.
71. Weiner HL, Komagata Y. (1998) Oral tolerance and the treatment of rheumatoid arthritis. Seminars Immunopathology 20:289-308.
72. Whang R. (1987) Magnesium deficiency: pathogenesis, prevalence and clinical implications. American Journal Medicine 82:24-29.
73. Whitehouse M. (2005) Prostanoids as friends not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats. Inflammopharmacology 12:481-492.
74. Whitehouse M. (2003) Thiocyanate from smoking amplifies inflammatory responses in rats. Inflammopharmacology 11:554-555.
75. Yuan G-H, Masuko-Hongo K, Kato T, Nishioka K. (2003) Immunological intervention in the pathologenesis of osteoarthritis. Arthritis Rheumatism 48:602-611.